+91 780-304-0404

Therapeutic and Preventive Vaccine Market

Global Therapeutic and Preventive Vaccine Market Size, Share & Trends Analysis Report by Type (Therapeutic Vaccine and Preventive Vaccine), By End-User (Human and Animal), and Forecast 2019-2025
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2020042 | Category : Pharmaceuticals | Delivery Format: /

The global therapeutic and preventive vaccine market is estimated to grow at an impressive growth rate of 9.3% during the forecast period. Vaccination is essential and helpful in managing chronic diseases. The high number of chronic diseases and the constant growth in it has motivated the government to focus on such diseases and its vaccination. Various methods and vaccination have been developed against a number of chronic diseases such as Hepatitis, Tuberculosis, Polio and so on. Significant R&D is also being conducted in other types of vaccination including DNA vaccination. Various organizations are also conducting researches related to chronic diseases such as cancers, HIV and so on. Papers and patents related to breast cancer, skin cancer, prostate cancer and others are published by the institutions in regular interval hence numerous inventions can be observed in the near future. 

Segmental Outlook  

The global therapeutic and preventive vaccine market is segmented on the basis of type, end-user, and region. On the basis of type, the market is broadly classified into the therapeutic vaccine and preventive vaccine. The global therapeutic vaccine market is analyzed on the basis of disease and vaccine type. On the basis of disease type, the therapeutic vaccine market is sub-segmented into autoimmune disease vaccine, neurological disease vaccine, and cancer vaccine. On the basis of vaccine type, the market is bifurcated into an allogeneic vaccine and autologous vaccine. 

Whereas, the global preventive vaccine market is further segmented on the basis of vaccine type and disease type. On the basis of vaccine type, the market is classified into live/attenuated vaccine, inactivated vaccine, conjugate vaccine, DNA vaccines, and others. Based on disease type, the market analyzes pneumococcal, poliovirus, hepatitis, influenza, measles, mumps, and rubella and other diseases. Based on the end-user, the global therapeutic and preventive vaccine market is divided into human and animal. 

Global Therapeutic and Preventive Vaccine Market Share by Type, 2018 (%)

Global Therapeutic and Preventive Vaccine Market Share by Type

Preventive Vaccine Estimated to Grow Impressively Over the Forecast Period

The preventive vaccines segment led the global therapeutic and preventive vaccine market in 2018 and is also estimated to grow impressively over the forecast period. The growth of the segment is primarily attributed to the growing focus on the R&D of DNA vaccines. A DNA vaccine uses a gene from a virus or bacteria to stimulate the immune system. The major factors that are motivating the segmental market growth include rising chronic diseases, increasing infectious diseases and lower cost of the vaccination. 

In particular to cancer, several types of research were carried out in recent times related to DNA vaccine and thus some vaccines are expected to be launched in the near future. For instance, Xenetic is working to create a broad pipeline of clinical candidates for next-generation novel oncology therapeutics and biologics in various orphan disease indications. DNA vaccination has appeared as a striking immunotherapeutic method against cancer due to its simplicity, stability, and safety. Results from numerous clinical trials have demonstrated that DNA vaccines are well tolerated by patients and do not trigger major adverse effects.

Regional Outlook 

Geographically, the study of the global therapeutic and preventive vaccine market covers the analysis of four major regions including North America (the US and Canada), Europe (Germany, UK, Italy, France, Italy, Spain, and Rest of Europe), and Rest of the World (RoW). North America led the global market in 2018 and is estimated to follow the same trend over the forecast period. The major factor for the growth of the market in the North American region includes the well-developed healthcare infrastructure, the number of researches carried out on vaccination and fund provided to the companies and institutions, unhealthy lifestyle and growing focus on the treatment of cancer.

Global Therapeutic and Preventive Vaccine Market Growth, by Region 2019-2025

Global Therapeutic and Preventive Vaccine Market Growth, by Region

Asia-Pacific to Be the Fastest-Growing Region During the Forecast Period

The Asia-Pacific is the fastest-growing region due to the increasing awareness about the benefits offered by vaccines. Major economies contributing to the market include China, Japan, India, South Korea, and Thailand. Factors such as the growing prevalence of cancer, unhealthy lifestyle, increasing disposable income, increasing awareness of people toward vaccination are driving the market. 

Moreover, strict regulations that mandate vaccination in economies such as China are further supporting the regional market growth. In China, it is mandatory to inject the hepatitis B vaccine (HBV) and tuberculosis-TB (BCG) vaccine immediately to the child after birth as per Chinese law. China began its expanded program on Immunization (EPI) in 1992. It involves a mandatory 11-vaccine schedule that must be given to children from 0 to 6 years. 

Market Players Outlook

Some of the key players operating in the global therapeutic and preventive vaccine market include Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Merck & Co., AstraZeneca PLC, and others. In order to remain competitive in the market, these market players adopt various strategies such as mergers and acquisitions, product offering expansion, geographical expansion, partnerships and collaborations, and others. Players operating in the market are also focusing on the market opportunities to capture the market share. 

For instance, in November 2016, GlaxoSmithKline PLC received FDA approval for an expanded indication for FluLaval Quadrivalent (Influenza Vaccine) for infants 6 months and older and it is approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older. Moreover, in February 2016, the company submitted a supplemental Biologics License Application (sBLA) to the FDA for its Flulaval Quadrivalent influenza vaccine. This vaccine is currently approved for active immunization against influenza A subtype viruses and type B viruses, in persons three years and older. The submission seeks an expanded indication for children six months through 35 months of age. 

The Report Covers

  • Market value data analysis of 2018 and forecast to 2025.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global therapeutic and preventive vaccine market. Based on the availability of data, information related to products and pipeline products, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report 

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Sanofi SA

3.3.1.1. Overview

3.3.1.2. Financial Analysis

3.3.1.3. SWOT Analysis

3.3.1.4. Recent Developments

3.3.2. Pfizer Inc.

3.3.2.1. Overview

3.3.2.2. Financial Analysis

3.3.2.3. SWOT Analysis

3.3.2.4. Recent Developments

3.3.3. GlaxoSmithKline PLC

3.3.3.1. Overview

3.3.3.2. Financial Analysis

3.3.3.3. SWOT Analysis

3.3.3.4. Recent Developments

3.3.4. Merck & Co.

3.3.4.1. Overview

3.3.4.2. Financial Analysis

3.3.4.3. SWOT Analysis

3.3.4.4. Recent Developments

3.3.5. AstraZeneca PLC

3.3.5.1. Overview

3.3.5.2. Financial Analysis

3.3.5.3. SWOT Analysis

3.3.5.4. Recent Developments

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. Global Therapeutic and Preventive Vaccine Market by Type

5.1.1. Therapeutic Vaccine

5.1.2. Preventive Vaccine

5.2. Global Therapeutic Vaccine Market by Disease Type 

5.2.1. Autoimmune Disease 

5.2.2. Neurological Disease 

5.2.3. Cancer 

5.2.4. Infectious Disease 

5.3. Global Therapeutic Vaccine Market by Vaccine Type 

5.3.1. Allogeneic Vaccine

5.3.2. Autologous Vaccine

5.4. Global Preventive Vaccine Market by Disease Type 

5.4.1. Pneumococcal

5.4.2. Poliovirus

5.4.3. Hepatitis

5.4.4. Influenza

5.4.5. Measles, Mumps, and Rubella

5.4.6. Others (Varicella)

5.5. Global Preventive Vaccine Market by Vaccine Type 

5.5.1. Live/Attenuated Vaccine

5.5.2. Inactivated Vaccine

5.5.3. Conjugate Vaccine

5.5.4. DNA Vaccines

5.5.5. Others (Recombinant Vector Vaccines)

5.6. Global Therapeutic and Preventive Vaccine Market by End-User

5.6.1. Human

5.6.2. Animal

6. Regional Analysis

6.1. North America

6.1.1. United States

6.1.2. Canada

6.2. Europe

6.2.1. UK

6.2.2. Germany

6.2.3. Italy

6.2.4. Spain

6.2.5. France

6.2.6. Rest of Europe

6.3. Asia-Pacific

6.3.1. China

6.3.2. Japan

6.3.3. India

6.3.4. Rest of Asia-Pacific

6.4. Rest of the World

7. Company Profiles

7.1. Agenus Inc.

7.2. Argos Therapeutic Inc.

7.3. Astellas Pharma Inc.

7.4. AstraZeneca PLC

7.5. Celldex Therapeutic Inc.

7.6. CSL Ltd.

7.7. Cytos Biotechnology AG

7.8. Daiichi Sankyo Co. Ltd

7.9. Dendreon Corp

7.10. Emergent BioSolutions Inc.

7.11. GC Pharma (Green Cross Corp.)

7.12. GlaxoSmithKline PLC

7.13. Johnson & Johnson Services Inc.

7.14. Merck & Co.

7.15. Novartis International AG

7.16. Novavax Inc.

7.17. Pfizer Inc.

7.18. Qed Biosciences Inc.

7.19. Sanofi SA

7.20. Takeda Pharmaceutical Co. Ltd.

7.21. Vaccinogen Inc.

7.22. Xenetic Biosciences, Inc.

7.23. Zoetis Inc.

1. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

2. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

3. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

4. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)

5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

6. GLOBAL NEUROLOGICAL DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

7. GLOBAL CANCER THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

8. GLOBAL INFECTIOUS DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

9. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2018-2025 ($ MILLION)

10. GLOBAL ALLOGENEIC THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

11. GLOBAL AUTOLOGOUS THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

12. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)

13. GLOBAL PREVENTIVE VACCINE FOR PNEUMOCOCCAL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

14. GLOBAL PREVENTIVE VACCINE FOR POLIOVIRUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

15. GLOBAL PREVENTIVE VACCINE FOR HEPATITIS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

16. GLOBAL PREVENTIVE VACCINE FOR INFLUENZA DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

17. GLOBAL PREVENTIVE VACCINE FOR MMR DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

18. GLOBAL PREVENTIVE VACCINE FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

19. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2018-2025 ($ MILLION)

20. GLOBAL LIVE/ATTENUATED PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

21. GLOBAL INACTIVATED PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

22. GLOBAL CONJUGATE PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

23. GLOBAL DNA PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

24. GLOBAL OTHER PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

25. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

26. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE FOR HUMAN MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

27. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE FOR ANIMAL MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

28. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)

29. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

30. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

31. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

32. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

33. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

34. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

35. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

36. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

37. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

38. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

39. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

1. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY TYPE, 2018 VS 2025 (%)

2. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY END-USER, 2018 VS 2025 (%)

3. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)

4. US THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

5. CANADA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

6. UK THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

7. FRANCE THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

8. GERMANY THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

9. ITALY THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

10. SPAIN THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

11. ROE THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

12. CHINA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

13. JAPAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

14. INDIA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

15. REST OF ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

16. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

Choose License Type
    On Discount

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports